Advances in the biological function of interleukin 38 and its study in immune diseases  

作　　者：Tian-Xiao Cui Cui-Ting Gong Ye Yerdingqmk Mizaniye Kaharv Xiao-Juan Zhou Ji-Yun Zhang 

机构地区：[1]Department of Rheumatology and Immunology,Second Hospital,Urumqi 830063,China

出　　处：《Microenvironment & Microecology Research》2023年第1期16-21,共6页微环境与微生态学研究（英文）

摘　　要：IL-38 is a newly discovered anti-inflammatory cytokine that belongs to the IL-1 family's IL-36 subfa+mily.Nonetheless,recent studies have shown that it can interact with multiple receptors to impede downstream signaling pathway activation,thereby restraining the differentiation and maturation of Th17 cells.While IL-38 enhances the immunosuppressive activity of Treg by inhibiting the transformation of CD4+T cells to Th17 cells,it can also exert its immune regulatory role by binding to the corresponding IL-38 receptor on the cell surface,which in turn inhibits classical signaling pathways such as NF-κB,P38,or JNK activation.IL-38 has been shown to alleviate disease progression in Rheumatoid Arthritis(RA),Systemic lupus erythematosus(SLE),cardiovascular disease(CVD),and other diseases by reducing the production of inflammatory cytokines and limiting the inflammatory response that is dependent on T cell subsets.Moreover,an increasing body of evidence suggests that IL-38 is a promising therapeutic target for these diseases.This article primarily reviews the immunological function of IL-38 and its involvement in related diseases,providing insights and theoretical support for chronic inflammatory and autoimmune diseases.

关 键 词：systemic lupus erythematosus interleukin-38 Th17 cells RECEPTORS 

分 类 号：R59[医药卫生—内科学]